Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill covid-19 patients. an observational study

HIGHLIGHTS

• who: Rafael Venegas-Rodru00edguez et al. from the Teaching Hospital, NIGERIA have published the research: Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study, in the Journal: PLOS ONE of January/24,/2022
• what: This paper presents the results of an observational and retrospective study on the therapeutic effects of Jusvinza an immunomodulatory peptide with anti-inflammatory properties for critically ill COVID-19 patients. The aim of this study is to describe the clinical outcome and variations of several inflammatory biomarkers in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.